Figure 1.

Schema for PROSPECT study. FOLFOX: 5FU/leucovorin + Oxaliplatin; CRT: chemoradiation therapy; LAR: low anterior resection; TME: total mesorectal excision; Cap: Capecitabine The PROSPECT study is evaluating preoperative RT followed by surgery and adjuvant therapy (the current standard of care) versus selective preoperative RT and evaluation before TME. The study aims to reduce the use of pelvic RT in patients who might not benefit from this treatment. All patients who meet criteria will be randomized in a 1:1 fashion.